ProtonDx key facts
- Developer of a portable molecular diagnostic platform designed to deliver rapid, laboratory-grade testing at the point of need.
- It has raised $11.4M; the latest was Grant ($1.1M) in Nov 2025.
- Notable investors include Innovate UK, UK Research and Innovation, Imperial College London Endowment, Imperial College London, MedTech SuperConnector — 6 tracked in total.
- Status: Privately Held (backing).
- ·Watch ProtonDx: the Monday email on marks, rounds and moves
ProtonDx funding rounds
No funding rounds for ProtonDx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
ProtonDx investors
6 investors are on record for ProtonDx, including Innovate UK, UK Research and Innovation, Imperial College London Endowment and Imperial College London.
About ProtonDx
Developer of a portable molecular diagnostic platform designed to deliver rapid, laboratory-grade testing at the point of need. The company offers compact lab-on-a-chip technology that provides PCR-equivalent analysis without a full laboratory, enabling healthcare and veterinary practitioners to gain improved access to fast, accurate diagnostics.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2020
- Employees
- 27
- Website
- protondx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
ProtonDx doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.